Seminars in Nuclear Medicine
Volume 36, Issue 2 , Pages 169-181 , April 2006

Gastrointestinal Tract Malignancies and Positron Emission Tomography: An Overview

References 

  1. Mauchley DC , Lynge DC , Langdale LA , et al.   Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer . Am J Surg . 2005;189:512–517 discussion 517
  2. Filippone A , Ambrosini R , Fuschi M , et al.   Preoperative T and N staging of colorectal cancer (Accuracy of contrast-enhanced multi-detector row CT colonography–initial experience) . Radiology . 2004;231:83–90
  3. Friedland S , Soetikno R , Carlisle M , et al.   18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer . Gastrointest Endosc . 2005;61:395–400
  4. Gutman F , Alberini JL , Wartski M , et al.   Incidental colonic focal lesions detected by FDG PET/CT . AJR Am J Roentgenol . 2005;185:495–500
  5. Kamel EM , Thumshirn M , Truninger K , et al.   Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT (Correlation with endoscopic and histopathologic results) . J Nucl Med . 2004;45:1804–1810
  6. van Kouwen MC , Nagengast FM , Jansen JB , et al.   2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon (a prospective study) . J Clin Oncol . 2005;23:3713–3717
  7. Abdel-Nabi H , Doerr RJ , Lamonica DM , et al.   Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET (Correlation with histopathologic and CT findings) . Radiology . 1998;206:755–760
  8. Mukai M , Sadahiro S , Yasuda S , et al.   Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer . Oncol Rep . 2000;7:85–87
  9. Kantorova I , Lipska L , Belohlavek O , et al.   Routine (18)F-FDG PET preoperative staging of colorectal cancer (Comparison with conventional staging and its impact on treatment decision making) . J Nucl Med . 2003;44:1784–1788
  10. August DA , Ottow RT , Sugarbaker PH . Clinical perspective of human colorectal cancer metastasis . Cancer Metastasis Rev . 1984;3:303–324
  11. Bipat S , van Leeuwen MS , Comans EF , et al.   Colorectal liver metastases (CT, MR imaging, and PET for diagnosis–meta-analysis) . Radiology . 2005;237:123–131
  12. Kinkel K , Lu Y , Both M , et al.   Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET) (A meta-analysis) . Radiology . 2002;224:748–756
  13. Staib L , Schirrmeister H , Reske SN , et al.   Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? . Am J Surg . 2000;180:1–5
  14. Valk PE , Abella-Columna E , Haseman MK , et al.   Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer . Arch Surg . 1999;134:503–511 discussion 511-503
  15. Whiteford MH , Whiteford HM , Yee LF , et al.   Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum . Dis Colon Rectum . 2000;43:759–767 discussion 767-770
  16. Lai DT , Fulham M , Stephen MS , et al.   The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver . Arch Surg . 1996;131:703–707
  17. Vitola JV , Delbeke D , Sandler MP , et al.   Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver . Am J Surg . 1996;171:21–26
  18. Delbeke D , Vitola JV , Sandler MP , et al.   Staging recurrent metastatic colorectal carcinoma with PET . J Nucl Med . 1997;38:1196–1201
  19. Hustinx R , Paulus P , Jacquet N , et al.   Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases . Ann Oncol . 1998;9:397–401
  20. Kalff V , Hicks RJ , Ware RE , et al.   The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer (A prospective study) . J Nucl Med . 2002;43:492–499
  21. Huebner RH , Park KC , Shepherd JE , et al.   A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer . J Nucl Med . 2000;41:1177–1189
  22. Moertel CG , Fleming TR , Macdonald JS , et al.   An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer . JAMA . 1993;270:943–947
  23. Fletcher RH . Carcinoembryonic antigen . Ann Intern Med . 1986;104:66–73
  24. McCall JL , Black RB , Rich CA , et al.   The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer . Dis Colon Rectum . 1994;37:875–881
  25. Engaras B . Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity . Dis Colon Rectum . 2003;46:313–321
  26. Flanagan FL , Dehdashti F , Ogunbiyi OA , et al.   Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer . Ann Surg . 1998;227:319–323
  27. Ruers TJ , Langenhoff BS , Neeleman N , et al.   Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases (a prospective study) . J Clin Oncol . 2002;20:388–395
  28. Venook A . Critical evaluation of current treatments in metastatic colorectal cancer . Oncologist . 2005;10:250–261
  29. Findlay M , Young H , Cunningham D , et al.   Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases (Correlation with tumor response to fluorouracil) . J Clin Oncol . 1996;14:700–708
  30. Kahn H , Alexander A , Rakinic J , et al.   Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0, N0 pathology . Dis Colon Rectum . 1997;40:140–144
  31. Guillem JG , Moore HG , Akhurst T , et al.   Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation (A means for determining longterm outcomes of rectal cancer) . J Am Coll Surg . 2004;199:1–7
  32. Amthauer H , Denecke T , Rau B , et al.   Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer (Correlation with endorectal ultrasound and histopathology) . Eur J Nucl Med Mol Imaging . 2004;31:811–819
  33. Barker DW , Zagoria RJ , Morton KA , et al.   Evaluation of liver metastases after radiofrequency ablation (utility of 18F-FDG PET and PET/CT) . AJR Am J Roentgenol . 2005;184:1096–1102
  34. Solbiati L , Livraghi T , Goldberg SN , et al.   Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer (long-term results in 117 patients) . Radiology . 2001;221:159–166
  35. Limanond P , Zimmerman P , Raman SS , et al.   Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies . AJR Am J Roentgenol . 2003;181:1635–1640
  36. Goldberg SN , Gazelle GS , Mueller PR . Thermal ablation therapy for focal malignancy (A unified approach to underlying principles, techniques, and diagnostic imaging guidance) . AJR Am J Roentgenol . 2000;174:323–331
  37. Lencioni R , Cioni D , Bartolozzi C . Percutaneous radiofrequency thermal ablation of liver malignancies (Techniques, indications, imaging findings, and clinical results) . Abdom Imaging . 2001;26:345–360
  38. Langenhoff BS , Oyen WJ , Jager GJ , et al.   Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases (a prospective study) . J Clin Oncol . 2002;20:4453–4458
  39. Donckier V , Van Laethem JL , Goldman S , et al.   [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases . J Surg Oncol . 2003;84:215–223
  40. Antoch G , Vogt FM , Veit P , et al.   Assessment of liver tissue after radiofrequency ablation (Findings with different imaging procedures) . J Nucl Med . 2005;46:520–525
  41. Dancey JE , Shepherd FA , Paul K , et al.   Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres . J Nucl Med . 2000;41:1673–1681
  42. Wong CY , Salem R , Raman S , et al.   Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET (A comparison with CT or MRI) . Eur J Nucl Med Mol Imaging . 2002;29:815–820
  43. Wong CY , Salem R , Qing F , et al.   Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases (Comparison of quantitative and visual analyses by 18F-FDG PET) . J Nucl Med . 2004;45:1892–1897
  44. Bienert M , McCook B , Carr BI , et al.   90Y microsphere treatment of unresectable liver metastases (Changes in 18F-FDG uptake and tumour size on PET/CT) . Eur J Nucl Med Mol Imaging . 2005;32:778–787
  45. Brunetti J , Caggiano A , Vialotti C . Functional anatomic imaging in radiation therapy planning . Cancer J . 2004;10:214–220
  46. Yasuda S , Raja S , Hubner KF . Application of whole-body positron emission tomography in the imaging of esophageal cancer (Report of a case) . Surg Today . 1995;25:261–264
  47. Sasaki M , Ichiya Y , Kuwabara Y , et al.   Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors . J Nucl Med . 1993;34:288–290
  48. Fukunaga T , Enomoto K , Okazumi S , et al.   [Analysis of glucose metabolism in patients with esophageal cancer by PET: Estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose] . Nippon Geka Gakkai Zasshi . 1994;95:317–325
  49. CMS Coverage Issues Manual Diagnostic Services. Available at: http://cms.hhs.gov/manuals/06_cim/ci50.asp#_50_36. Accessed March 1, 2004
  50. Torizuka T , Zasadny KR , Wahl RL . Diabetes decreases FDG accumulation in primary lung cancer . Clin Positron Imaging . 1999;2:281–287
  51. van Westreenen HL , Cobben DC , Jager PL , et al.   Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer . J Nucl Med . 2005;46:400–404
  52. Jager PL , Que TH , Vaalburg W , et al.   Carbon-11 choline or FDG-PET for staging of oesophageal cancer? . Eur J Nucl Med . 2001;28:1845–1849
  53. Flamen P , Lerut A , Van Cutsem E , et al.   Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma . J Clin Oncol . 2000;18:3202–3210
  54. Yoon YC , Lee KS , Shim YM , et al.   Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma (CT versus FDG PET for presurgical detection prospective study) . Radiology . 2003;227:764–770
  55. Gambhir SS , Czernin J , Schwimmer J , et al.   A tabulated summary of the FDG PET literature . J Nucl Med . 2001;42:1S–93S
  56. Skehan SJ , Brown AL , Thompson M , et al.   Imaging features of primary and recurrent esophageal cancer at FDG PET . Radiographics . 2000;20:713–723
  57. Fukunaga T , Okazumi S , Koide Y , et al.   Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET . J Nucl Med . 1998;39:1002–1007
  58. Kim K , Park SJ , Kim BT , et al.   Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography . Ann Thorac Surg . 2001;71:290–294
  59. Flanagan FL , Dehdashti F , Siegel BA , et al.   Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography . AJR Am J Roentgenol . 1997;168:417–424
  60. Block MI , Patterson GA , Sundaresan RS , et al.   Improvement in staging of esophageal cancer with the addition of positron emission tomography . Ann Thorac Surg . 1997;64:770–776 discussion 776-777
  61. Heeren PA , Jager PL , Bongaerts F , et al.   Detection of distant metastases in esophageal cancer with (18)F-FDG PET . J Nucl Med . 2004;45:980–987
  62. Sihvo EI , Rasanen JV , Knuuti MJ , et al.   Adenocarcinoma of the esophagus and the esophagogastric junction (Positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease) . J Gastrointest Surg . 2004;8:988–996
  63. Flamen P , Lerut T , Haustermans K , et al.   Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer . Q J Nucl Med Mol Imaging . 2004;48:96–108
  64. Patel AN , Buenaventura PO . Current staging of esophageal carcinoma . Surg Clin North Am . 2005;85:555–567
  65. NCCN Clinical Practice Guidelines in Oncology. Esophageal Cancer. Version 1.2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf. Accessed October 12, 2005
  66. Dehdashti F , Siegel BA . Neoplasms of the esophagus and stomach . Semin Nucl Med . 2004;34:198–208
  67. Luketich JD , Schauer PR , Meltzer CC , et al.   Role of positron emission tomography in staging esophageal cancer . Ann Thorac Surg . 1997;64:765–769
  68. Luketich JD , Friedman DM , Weigel TL , et al.   Evaluation of distant metastases in esophageal cancer (100 consecutive positron emission tomography scans) . Ann Thorac Surg . 1999;68:1133–1136 discussion 1136-1137
  69. Meltzer CC , Luketich JD , Friedman D , et al.   Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography . Clin Nucl Med . 2000;25:882–887
  70. Choi JY , Lee KH , Shim YM , et al.   Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET . J Nucl Med . 2000;41:808–815
  71. Bar-Shalom R , Guralnik L , Tsalic M , et al.   The additional value of PET/CT over PET in FDG imaging of oesophageal cancer . Eur J Nucl Med Mol Imaging . 2005;32:918–924
  72. Lerut T , Flamen P , Ectors N , et al.   Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction (A prospective study based on primary surgery with extensive lymphadenectomy) . Ann Surg . 2000;232:743–752
  73. Wallace MB , Nietert PJ , Earle C , et al.   An analysis of multiple staging management strategies for carcinoma of the esophagus (Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy) . Ann Thorac Surg . 2002;74:1026–1032
  74. Brucher BL , Weber W , Bauer M , et al.   Neoadjuvant therapy of esophageal squamous cell carcinoma (Response evaluation by positron emission tomography) . Ann Surg . 2001;233:300–309
  75. Downey RJ , Akhurst T , Ilson D , et al.   Whole body 18FDG-PET and the response of esophageal cancer to induction therapy (Results of a prospective trial) . J Clin Oncol . 2003;21:428–432
  76. Weber WA , Ott K , Becker K , et al.   Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging . J Clin Oncol . 2001;19:3058–3065
  77. Cerfolio RJ , Bryant AS , Ohja B , et al.   The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy . J Thorac Cardiovasc Surg . 2005;129:1232–1241
  78. Brink I , Hentschel M , Bley TA , et al.   Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma . Eur J Surg Oncol . 2004;30:544–550
  79. Arslan N , Miller TR , Dehdashti F , et al.   Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer . Mol Imaging Biol . 2002;4:301–310
  80. Nakamura R , Obara T , Katsuragawa S , et al.   Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy . Radiat Med . 2002;20:181–186
  81. Song SY , Kim JH , Ryu JS , et al.   FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer . Int J Radiat Oncol Biol Phys . 2005;63:1053–1059
  82. Westerterp M , van Westreenen HL , Reitsma JB , et al.   Esophageal cancer (CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review) . Radiology . 2005;236:841–851
  83. Peller P , Rauth J , Norby E . PET scan evaluation of preoperative chemoradiotherapy in locally advanced esophageal cancer (an accurate predictor of postsurgical outcome) . Radiol Soc N Am . 2004; (abstr)
  84. Vrieze O , Haustermans K , De Wever W , et al.   Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? . Radiother Oncol . 2004;73:269–275
  85. Konski A , Doss M , Milestone B , et al.   The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma . Int J Radiat Oncol Biol Phys . 2005;61:1123–1128
  86. Flamen P , Lerut A , Van Cutsem E , et al.   The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer . J Thorac Cardiovasc Surg . 2000;120:1085–1092
  87. Stahl A , Ott K , Weber WA , et al.   FDG PET imaging of locally advanced gastric carcinomas (Correlation with endoscopic and histopathological findings) . Eur J Nucl Med Mol Imaging . 2003;30:288–295
  88. Yun M , Lim JS , Noh SH , et al.   Lymph node staging of gastric cancer using 18F-FDG PET (A comparison study with CT) . J Nucl Med . 2005;46:1582–1588
  89. De Potter T , Flamen P , Van Cutsem E , et al.   Whole-body PET with FDG for the diagnosis of recurrent gastric cancer . Eur J Nucl Med Mol Imaging . 2002;29:525–529
  90. Ott K , Fink U , Becker K , et al.   Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging (Results of a prospective trial) . J Clin Oncol . 2003;21:4604–4610
  91. Hersh MR , Choi J , Garrett C , et al.   Imaging gastrointestinal stromal tumors . Cancer Control . 2005;12:111–115
  92. Goerres GW , Stupp R , Barghouth G , et al.   The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours (Long-term outcome of treatment with imatinib mesylate) . Eur J Nucl Med Mol Imaging . 2005;32:153–162
  93. Gayed I , Vu T , Iyer R , et al.   The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors . J Nucl Med . 2004;45:17–21
  94. Lee JD , Yang WI , Park YN , et al.   Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake . J Nucl Med . 2005;46:1753–1759
  95. Lin WY , Tsai SC , Hung GU . Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma . Nucl Med Commun . 2005;26:315–321
  96. Ho CL , Yu SC , Yeung DW . 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses . J Nucl Med . 2003;44:213–221
  97. Sugiyama M , Sakahara H , Torizuka T , et al.   18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma . J Gastroenterol . 2004;39:961–968
  98. Anderson CD , Rice MH , Pinson CW , et al.   Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma . J Gastrointest Surg . 2004;8:90–97
  99. Orlando LA , Kulasingam SL , Matchar DB . Meta-analysis (the detection of pancreatic malignancy with positron emission tomography) . Aliment Pharmacol Ther . 2004;20:1063–1070
  100. Adams S , Baum R , Rink T , et al.   Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours . Eur J Nucl Med . 1998;25:79–83

PII: S0001-2998(05)00071-1

doi: 10.1053/j.semnuclmed.2005.12.002

Seminars in Nuclear Medicine
Volume 36, Issue 2 , Pages 169-181 , April 2006

Article Tools

* Image Usage & Resolution